---
title: 'Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell
  Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis'
date: '2024-04-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38612799/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240414191153&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer
  (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib
  is the only approved TKI specifically designed to target EGFR Ex20. We performed
  an international, real-world safety and efficacy analysis on patients with EGFR
  Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored
  the mechanisms of resistance by analyzing postprogression biopsies, as well ...
disable_comments: true
---
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well ...